A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response

Autor: Michael L. Pearl, Emily K. Hill, Joan L. Walker, William H. Rodgers, Virginia L. Filiaci, Heather A. Lankes, Kimberly K. Leslie, Elise C. Kohn, Kari L. Ring, Anand Rajan, Carolyn Y. Muller, Laura L. Holman, Linda R. Duska, Christina L. Kushnir, Richard G. Moore, Kelley Carrick, Megan I. Samuelson, Richard Piekarz

Publikováno v: Clin Cancer Res

Purpose: This surgical window of opportunity (window) study assessed the short-term effect of medroxyprogesterone acetate (MPA) alone versus MPA plus the histone deacetylase (HDAC) inhibitor entinostat on regulation of progesterone receptor (PR) in w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f2c594c3cbdcc4926ee61b4f6fbdabd
https://pubmed.ncbi.nlm.nih.gov/33766814

Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis

Autor: Ellen M. Hartenbach, Christina L. Kushnir, David M. O'Malley, Joan L. Walker, Natalie S. Gould, William H. Rodgers, Meaghan Tenney, Michael L. Pearl, Robert S. Mannel, Stephanie Ricci, Sarah M. Temkin, James J. Java, Chad A. Hamilton, Nick M. Spirtos, Amanda N. Fader, Oliver Zivanovic, Camille C. Gunderson, Krishnansu S. Tewari

Publikováno v: Fader, AN; Java, J; Tenney, M; Ricci, S; Gunderson, CC; Temkin, SM; et al.(2016). Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecologic Oncology, 143(3), 460-465. doi: 10.1016/j.ygyno.2016.10.016. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/3xf925hz

© 2016 Elsevier Inc. Objectives We sought to analyze the clinicopathologic features, recurrence patterns and survival outcomes of women with high-grade uterine cancer (UC) enrolled on The Gynecologic Oncology Group (GOG) LAP2 trial. Methods This is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74462db12b871a77038378ea66eff0f5
https://doi.org/10.1016/j.ygyno.2016.10.016

Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD)

Autor: Angeles Alvarez Secord, D. Spahlinger, Ana M. Angarita, S.D. Thompson, Christina L. Kushnir, Edward J. Tanner, Abdulrahman K. Sinno, Amanda N. Fader, Rebecca L. Stone, Kara Long Roche, Laura J. Havrilesky

Publikováno v: Gynecologic Oncology. 137:503-507

Objective The study objective was to examine the safety and cost savings of selective cardiac surveillance (CS) during treatment with pegylated liposomal doxorubicin (PLD). Methods A retrospective, dual institution study of women receiving PLD for th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05d856134ab0bb4d982a0de09d3b8e9f
https://doi.org/10.1016/j.ygyno.2015.02.020

Evaluation of exposures to healthcare personnel from cisplatin during a mock demonstration of intra-operative intraperitoneal chemotherapy administration

Autor: Aimee C. Fleury, James R. Couch, Nick M. Spirtos, Michael C. Hill, Christina L. Kushnir

Publikováno v: Gynecologic Oncology. 130:350-353

Ovarian cancer is the leading cause of death from gynecologic malignancies in the United States. In 2006, the National Cancer Institute released an announcement supporting the use of intraperitoneal (IP) chemotherapy in advanced ovarian cancer. It re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bd803b6d9b19f92f28c29ea03192b62
https://doi.org/10.1016/j.ygyno.2013.04.467

Intraperitoneal Catheter Placement: The 'Hammock' Technique

Autor: Aimee C. Fleury, Nick M. Spirtos, Christina L. Kushnir, David Silver

Publikováno v: Clinical Ovarian and Other Gynecologic Cancer. 5:24-26

Background Ovarian cancer is the leading cause of death from gynecologic malignancies in the United States. The NCI released a clinical announcement supporting the use of intraperitoneal chemotherapy in addition to intravenous chemotherapy. However,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9263a58bd854dcd78101a372374f4734
https://doi.org/10.1016/j.cloc.2011.08.001